Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.
相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
尚未招募
1
50.0%
招募中
1
50.0%
暂无批准数据
- Mainz Biomed's feasibility study demonstrated 100% sensitivity and 95% specificity for pancreatic cancer detection using a non-invasive blood-based screening test in a 30-subject cohort. - The company licensed proprietary mRNA biomarkers from Liquid Biosciences that achieved 95% sensitivity and 98% specificity in initial discovery studies across 285 subjects including 35 pancreatic cancer patients. - The pancreatic cancer project received public funding from Germany's ISB development bank, covering up to 50% of total project costs under their Innovation and Technology Support Program. - Mainz Biomed also expanded its colorectal cancer screening test ColoAlert to new markets including the UK, Switzerland, and South America through strategic partnerships.
- Mainz Biomed has commercially launched ColoAlert, its DNA-based colorectal cancer screening test, in Switzerland following Swissmedic regulatory approval and a strategic partnership with labor team w ag diagnostic laboratory. - The non-invasive stool-based test detects DNA biomarkers for early colorectal cancer detection and is now available to patients and healthcare providers throughout Switzerland through an established laboratory network. - The company continues enrollment in its 2,000-patient eAArly DETECT 2 study with plans to complete recruitment by end of 2025, while ColoAlert has also received MHRA registration for marketing in the United Kingdom.
- Mainz Biomed has secured exclusive licensing rights to novel mRNA biomarkers discovered by Liquid Biosciences for blood-based pancreatic cancer detection, achieving 95% sensitivity and 98% specificity in initial studies. - The groundbreaking technology utilizes Liquid Biosciences' proprietary EMERGE platform and machine learning algorithms to identify clinically relevant biomarkers from multiple independent pancreatic cancer cohorts. - The companies plan to jointly develop this non-invasive screening test with potential to become the most accurate pancreatic cancer detection method on the market, preparing for future FDA application and approval.
- Mainz Biomed has established a strategic partnership with labor team w ag in Switzerland to introduce ColoAlert, a DNA-based colorectal cancer screening test, marking its first entry into the Swiss market. - The collaboration leverages Mainz Biomed's advanced DNA diagnostic capabilities alongside labor team w ag's established laboratory expertise to enhance cancer screening accessibility in Switzerland. - This expansion represents a significant milestone in Mainz Biomed's European market growth strategy and introduces innovative cancer detection technology to Swiss healthcare providers.
- Mainz Biomed and Quest Diagnostics have partnered to enhance the commercialization of Mainz Biomed's NextGen colorectal cancer screening test. - Quest Diagnostics will provide laboratory services for Mainz Biomed's ReconAAsense study, involving 15,000 participants across 150 U.S. sites. - Mainz Biomed has initiated eAArly DETECT 2, a U.S. feasibility study to evaluate its next-generation colorectal cancer test with mRNA biomarkers. - The ColoAlert test, marketed in Europe and the UAE, utilizes PCR technology on stool samples to detect colorectal cancer tumor DNA.
